+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID04789486

Study of AGuIX Nanoparticles With MR-Guided Stereotactic Body Radiation Therapy for Lung Tumors and Advanced Pancreatic Cancer Phase I-II Trial to Evaluate Safety and Effectiveness

Led by Dana-Farber Cancer Institute · Updated on 2026-05-14

100

Participants Needed

2

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a gadolinium-based nanoparticle called Activation and Guidance of Irradiation X AGuIX combined with magnetic resonance MR-guided stereotactic body radiation therapy SBRT for treating pancreatic cancer and centrally located lung tumors. This phase III trial includes two separate groups patients with central lung tumors and those with locally advanced or unresectable pancreatic ductal adenocarcinoma. The study aims to find a safe dose and then test how well this combination works compared to standard MR-guided adaptive radiation therapy SMART alone. Participants in the first phase receive escalating doses of AGuIX nanoparticles along with SMART radiation therapy. Those with central lung tumors get five SBRT treatments plus AGuIX doses given before and during radiation. Patients with pancreatic cancer receive five SBRT treatments with AGuIX given before and at the start of radiation. In the second phase, participants are randomly assigned to receive either the established safe dose of AGuIX plus SMART or SMART alone to compare treatment effects. During the study, participants undergo screening and evaluations before treatment, receive five days of study treatment, and are followed for one year afterward. Researchers monitor tumor response, side effects, quality of life, and survival outcomes using imaging and health assessments. The main goals include finding the maximum tolerated dose and comparing tumor control at 12 months between treatments. Safety and other health measures are assessed throughout and after treatment.

CONDITIONS

Brief Title

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Research Team

J

Jonathan Leeman, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here